Last reviewed · How we verify
Auotologous AMSCs plus autologous PRP — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Auotologous AMSCs plus autologous PRP (Auotologous AMSCs plus autologous PRP) — Yantai Yuhuangding Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Auotologous AMSCs plus autologous PRP TARGET | Auotologous AMSCs plus autologous PRP | Yantai Yuhuangding Hospital | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Auotologous AMSCs plus autologous PRP CI watch — RSS
- Auotologous AMSCs plus autologous PRP CI watch — Atom
- Auotologous AMSCs plus autologous PRP CI watch — JSON
- Auotologous AMSCs plus autologous PRP alone — RSS
Cite this brief
Drug Landscape (2026). Auotologous AMSCs plus autologous PRP — Competitive Intelligence Brief. https://druglandscape.com/ci/auotologous-amscs-plus-autologous-prp. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab